Release Date: June 30, 2025
Expiration Date: June 30, 2026
Activity Overview
Recent advances in the treatment of presbyopia have focused on pharmacological agents as a novel therapeutic strategy that offers noninvasive, reversible options capable of enhancing depth of focus without altering the natural lens structure. As new and emerging pharmacological therapies show potential in restoring near vision through modulation of pupillary dynamics, the mechanisms of action, safety profiles, and durability of effect must be critically evaluated to guide evidence-based treatment decisions. Their implementation in clinical practice necessitates an in-depth understanding of their impact on pupil size, accommodation, and ocular surface health, as well as potential risks such as retinal traction or vitreoretinal complications in predisposed patients.
Given the ongoing refinement of these therapies, clinicians must remain vigilant to the long-term safety and efficacy considerations, especially as new compounds are explored and the pharmacological landscape for presbyopia continues to evolve. This educational symposium, featuring expert presentations and discussion, enables a nuanced understanding of the comparative utility of these agents and also fosters informed discussions around optimizing outcomes for diverse patient populations, ensuring that the adoption of these treatments is both scientifically grounded and patient centered.
This educational activity is an archive of the live virtual symposium held on May 4, 2025.
Target Audience
This educational activity is directed toward ophthalmologists, optometrists, ophthalmic/optometric technicians, and other eye care professionals involved in the treatment of patients with presbyopia.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize recommended diagnostic techniques for presbyopia
- Analyze the efficacy and safety data associated with new and emerging presbyopia pharmacologic treatments
- Apply strategies to enhance patient quality of life (QOL) following the administration of novel presbyopia therapies
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here